→
Avoid the hepatic first-pass effect
During conventional oral administration, the drug is metabolized during its first pass through the liver, which reduces its efficacy before reaching systemic circulation.
Why this innovation?
New oro-mucosal administration approaches address specific clinical and therapeutic needs in terms of speed of action, efficacy, and tolerability.
→
Improve the bioavailability of certain molecules
Lipophilic or amphiphilic molecules benefit from rapid absorption through the highly vascularized oral mucosa.
→
Meet the need for rapid action
The buccal transmucosal route allows for a comparable speed of action to that of an intravenous injection.
→
Reduce the doses administered and adverse effects
By avoiding the hepatic first-pass effect, the quantity of active ingredient to be delivered with each dose is reduced, thus limiting the potential adverse effects of the drug.
The solution: what it changes
Uniflash®
Benefits for patients
Uniflash® is a single-dose oro-mucosal solution to be administered orally. The efficacy and speed of action of this new non-invasive transmucosal delivery route are comparable to that of an intravenous injection.
- Elimination of the famous ‘hepatic first-pass effect’*
- Improved absorption with the oral route
- Reduction in the amount of active ingredient administered: increased drug safety, lower risk of overdose
- Optimal speed of action
*The hepatic first-pass effect refers to the metabolism of the drug during its first pass through the liver, before reaching systemic circulation, during oral administration.
uniflash-petit-format stick
Technology
- Patented oro-mucosal solution
- Liquid stick pack: a pre-measured, ready-to-use, portable format that allows treatments to be taken without water
- Stick pack opening specially designed to facilitate oral administration
- Mini stick pack format (1 to 2ml): practical advantage, contributing to proper use
Manufacturing sites
All our French sites are subject to inspections by European authorities, allowing us to manufacture products for European markets. The Coutances and Amiens sites (France) are regularly inspected by the ANSM (French National Agency for the Safety of Medicines and Health Products), the FDA (U.S. Food and Drug Administration), the KFDA (Korean Food and Drug Administration), and other international health authorities.
